Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424311 | 0.84 | BCAT1 (0.33) | BCAT1PDE5AELANEF2PLAU | |
| SCHEMBL25205878 | 0.84 | BCAT1 (0.33) | BCAT1PDE5AELANEF2PLAU | |
| SCHEMBL30424181 | 0.81 | TEAD1 (0.45) | SCN9A | |
| SCHEMBL25230361 | 0.81 | TEAD1 (0.45) | SCN9A | |
| SCHEMBL25751171 | 0.80 | PDE5A (0.35) | PDE5ASCN9A | |
| SCHEMBL25751193 | 0.68 | — | — | |
| SCHEMBL25747946 | 0.67 | KMT2A (0.37) | PDE5A | |
| SCHEMBL30423991 | 0.65 | PDE5A (0.34) | PDE5ASCN9A | |
| SCHEMBL25230337 | 0.65 | PDE5A (0.34) | PDE5ASCN9A | |
| SCHEMBL30201876 | 0.64 | BCAT1 (0.66) | BCAT1PDE5AELANEF2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | BCAT1 2924/4885PDE5A 1909/4885ELANE 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.